Apeiron Biologics AG, of Vienna, closed a financing round of €17.5 million (US$19.7 million). The round includes an equity investment of €11.9 million from existing and new private and institutional investors, including the Vienna Insurance Group, and €5.6 million in public funding and guarantees from the Austrian Research Agency, the Vienna Business Agency, the Austria Economic Service Co. and Erste Bank. Apeiron plans to use the proceeds to fund the development of APN-01, a treatment for seriously ill COVID-19 patients, and the further development of immuno-oncology projects.
Appili Therapeutics Inc., of Halifax, Nova Scotia, said it priced an overnight marketed offering of equity securities and issued 11.25 million units at CA$1.20 each for gross proceeds of CA$13.5 million (US$9.99 million). Each unit comprises one class A common share and one-half of one common share purchase warrant, with a warrant exercisable at CA$1.50. The net proceeds will be used primarily toward funding planned research and development activities for the clinical trial sponsored by the company evaluating Tokyo-based Fujifilm Toyama Chemical Inc.’s favipiravir in long-term care facilities as a potential preventive measure against COVID-19. Proceeds will also be used to fund development costs for the company’s other product candidates, including the ATI-2307 antifungal program, the ATI-1701 tularemia vaccine program and the antibiotic ATI-1503 program, as well as for working capital and general corporate purposes.
Bionomics Ltd., of Adelaide, Australia, said it entered a subscription agreement with Apeiron Investment Group Ltd. to recapitalize the company and assist in securing further equity capital. Under the subscription agreement, Apeiron agrees to subscribe or procure subscriptions of about 135.8 million shares at an issue price of AU4 cents (US2.7 cents) per share to raise AU$5.4 million (to proceed in two tranches of 81.5 million shares and 54.3 million shares, the second being subject to shareholder approval). Apeiron also agrees to underwrite further capital raisings by Bionomics within a 15-month-period from the extraordinary general meeting of shareholders to be convened, with the effect that Bionomics will raise up to AU$15 million at a minimum issue price of AU6 cents per share subject to approvals.
Humanigen Inc., of Burlingame, Calif., priced a private placement of about $72 million of common stock. Net proceeds will be used to fund development of the company's monoclonal antibody portfolio and for general corporate purposes, including the pivotal phase III trial of lenzilumab for the prevention and treatment of cytokine storm in COVID-19 pneumonia and the development of Humanigen's pipeline, including ZUMA-19, the CAR T study involving lenzilumab being conducted in collaboration with Kite Pharma, a unit of Foster City, Calif.-based Gilead Sciences Inc. J.P. Morgan Securities LLC is acting as the placement agent for the financing, which comprises a group of health care investors including Venrock Healthcare Capital Partners, Surveyor Capital, Healthcor, Valiant Capital Partners, First Light Asset Management and Ghost Tree Capital.
Outlook Therapeutics Inc., of Monmouth, Junction, N.J., closed its private placement of 16 million shares at $1 per share to Syntone Ventures LLC. The company plans to use the proceeds for working capital and general corporate purposes, including development of Lytenva (bevacizumab-vikg) for wet age-related macular degeneration; approximately $900,000 of the proceeds will be used to fund the initial capital contribution to the planned joint venture with Syntone in China.